1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

16 Apr 2024
Admin
News Article

AstraZeneca’s Fasenra Receives FDA Approval

AstraZeneca’s Fasenra receives FDA approval for paediatric patients with severe asthma

Overview

Severe eosinophilic asthma causes inflammation in the lungs and airways of patients AstraZeneca (AZ) has announced that its Fasenra (benralizumab) has received expanded approval from the US Food and Drug Administration (FDA) as an add-on maintenance treatment for paediatric patients aged six to 11 years with severe eosinophilic asthma (SEA).

Behind Approval

The approval was based on evidence from the open-label phase 3 TATE trial in addition to well-controlled trials in adult and adolescent populations.

Asthma

Asthma is one of the most common chronic childhood diseases and causes coughing, wheezing and difficulty breathing.
SEA is a serious form of asthma that occurs when white blood cells known as eosinophils become overreactive and cause inflammation in the lungs and airways.

Monoclonal antibody- Fasenra is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils, attracting cells to deplete blood and tissue eosinophils in most patients via programmed cell death.

TATE Study Outcomes

Results from the TATE study demonstrated that Fasenra met its primary endpoints after exhibiting pharmacokinetics and pharmacodynamics in paediatric patients aged six to 11 years with SEA, which were consistent with those seen in previous trials, as well as its safety and tolerability.

Recommended Dose for Kids

Administered via a subcutaneous injection, the recommended dose for Fasenra in patients aged six and older who weigh 35kg or more is 30mg, while paediatric patients aged six to 11 years who weigh less than 35kg will now require a 10mg dose.

Liz Bodin, vice president, US respiratory and immunology, AZ, said: “Expanding options for children whose quality of life has been drastically impacted by SEA with the help of Fasenra is an exciting step in our mission to revolutionise asthma care.”

Wordds from Allergy and Asthma Network

Chief audit executive and chief executive officer of the Allergy and Asthma Network, Lynda Mitchell, commented: “We welcome additional treatment options for children living with severe asthma… further helping to address the unmet need in this patient population and reducing the burden of disease for the broader asthma community.”

Previous Approvals

Already authorised in more than 80 countries, Fasenra was first approved by the FDA in 2017, as an add-on maintenance treatment for paediatric patients aged 12 years and older with SEA.

Monoclonal Antibody: Indications

The monoclonal antibody is also currently in development to treat other diseases, including chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps and hypereosinophilic syndrome.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!